The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Glioblastoma Multiforme Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor.
The global Glioblastoma Multiforme Therapeutics market size is expected to reach US$ 996.4 million by 2029, growing at a CAGR of 8.8% from 2023 to 2029. The market is mainly driven by the significant applications of Glioblastoma Multiforme Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Glioblastoma Multiforme Therapeutics market. Temozolomide, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Bevacozumab segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Glioblastoma Multiforme Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Glioblastoma Multiforme Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Glioblastoma Multiforme Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Glioblastoma Multiforme Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Glioblastoma Multiforme Therapeutics covered in this report include Arbor Pharmaceuticals, Bristol-Myers Squibb, Eisai, F. Hoffmann-La Roche and Merck, etc.
The global Glioblastoma Multiforme Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Arbor Pharmaceuticals
Bristol-Myers Squibb
Eisai
F. Hoffmann-La Roche
Merck
Global Glioblastoma Multiforme Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Glioblastoma Multiforme Therapeutics market, Segment by Type:
Temozolomide
Bevacozumab
Carmustine
Global Glioblastoma Multiforme Therapeutics market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Glioblastoma Multiforme Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Glioblastoma Multiforme Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor.
The global Glioblastoma Multiforme Therapeutics market size is expected to reach US$ 996.4 million by 2029, growing at a CAGR of 8.8% from 2023 to 2029. The market is mainly driven by the significant applications of Glioblastoma Multiforme Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Glioblastoma Multiforme Therapeutics market. Temozolomide, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Bevacozumab segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Glioblastoma Multiforme Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Glioblastoma Multiforme Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Glioblastoma Multiforme Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Glioblastoma Multiforme Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Glioblastoma Multiforme Therapeutics covered in this report include Arbor Pharmaceuticals, Bristol-Myers Squibb, Eisai, F. Hoffmann-La Roche and Merck, etc.
The global Glioblastoma Multiforme Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Arbor Pharmaceuticals
Bristol-Myers Squibb
Eisai
F. Hoffmann-La Roche
Merck
Global Glioblastoma Multiforme Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Glioblastoma Multiforme Therapeutics market, Segment by Type:
Temozolomide
Bevacozumab
Carmustine
Global Glioblastoma Multiforme Therapeutics market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Glioblastoma Multiforme Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Glioblastoma Multiforme Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Glioblastoma Multiforme Therapeutics Market Overview
1.1 Glioblastoma Multiforme Therapeutics Product Overview
1.2 Glioblastoma Multiforme Therapeutics Market Segment by Type
1.2.1 Temozolomide
1.2.2 Bevacozumab
1.2.3 Carmustine
1.3 Global Glioblastoma Multiforme Therapeutics Market Size by Type
1.3.1 Global Glioblastoma Multiforme Therapeutics Market Size Overview by Type (2018-2029)
1.3.2 Global Glioblastoma Multiforme Therapeutics Historic Market Size Review by Type (2018-2023)
1.3.3 Global Glioblastoma Multiforme Therapeutics Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Glioblastoma Multiforme Therapeutics Sales Breakdown by Type (2018-2023)
1.4.2 Europe Glioblastoma Multiforme Therapeutics Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Glioblastoma Multiforme Therapeutics Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Glioblastoma Multiforme Therapeutics Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Glioblastoma Multiforme Therapeutics Sales Breakdown by Type (2018-2023)
2 Global Glioblastoma Multiforme Therapeutics Market Competition by Company
2.1 Global Top Players by Glioblastoma Multiforme Therapeutics Sales (2018-2023)
2.2 Global Top Players by Glioblastoma Multiforme Therapeutics Revenue (2018-2023)
2.3 Global Top Players by Glioblastoma Multiforme Therapeutics Price (2018-2023)
2.4 Global Top Manufacturers Glioblastoma Multiforme Therapeutics Manufacturing Base Distribution, Sales Area, Product Type
2.5 Glioblastoma Multiforme Therapeutics Market Competitive Situation and Trends
2.5.1 Glioblastoma Multiforme Therapeutics Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Glioblastoma Multiforme Therapeutics Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Glioblastoma Multiforme Therapeutics as of 2022)
2.7 Date of Key Manufacturers Enter into Glioblastoma Multiforme Therapeutics Market
2.8 Key Manufacturers Glioblastoma Multiforme Therapeutics Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Glioblastoma Multiforme Therapeutics Status and Outlook by Region
3.1 Global Glioblastoma Multiforme Therapeutics Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Glioblastoma Multiforme Therapeutics Historic Market Size by Region
3.2.1 Global Glioblastoma Multiforme Therapeutics Sales in Volume by Region (2018-2023)
3.2.2 Global Glioblastoma Multiforme Therapeutics Sales in Value by Region (2018-2023)
3.2.3 Global Glioblastoma Multiforme Therapeutics Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Glioblastoma Multiforme Therapeutics Forecasted Market Size by Region
3.3.1 Global Glioblastoma Multiforme Therapeutics Sales in Volume by Region (2024-2029)
3.3.2 Global Glioblastoma Multiforme Therapeutics Sales in Value by Region (2024-2029)
3.3.3 Global Glioblastoma Multiforme Therapeutics Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Glioblastoma Multiforme Therapeutics by Application
4.1 Glioblastoma Multiforme Therapeutics Market Segment by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Others
4.2 Global Glioblastoma Multiforme Therapeutics Market Size by Application
4.2.1 Global Glioblastoma Multiforme Therapeutics Market Size Overview by Application (2018-2029)
4.2.2 Global Glioblastoma Multiforme Therapeutics Historic Market Size Review by Application (2018-2023)
4.2.3 Global Glioblastoma Multiforme Therapeutics Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Glioblastoma Multiforme Therapeutics Sales Breakdown by Application (2018-2023)
4.3.2 Europe Glioblastoma Multiforme Therapeutics Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Glioblastoma Multiforme Therapeutics Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Glioblastoma Multiforme Therapeutics Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Glioblastoma Multiforme Therapeutics Sales Breakdown by Application (2018-2023)
5 North America Glioblastoma Multiforme Therapeutics by Country
5.1 North America Glioblastoma Multiforme Therapeutics Historic Market Size by Country
5.1.1 North America Glioblastoma Multiforme Therapeutics Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Glioblastoma Multiforme Therapeutics Sales in Volume by Country (2018-2023)
5.1.3 North America Glioblastoma Multiforme Therapeutics Sales in Value by Country (2018-2023)
5.2 North America Glioblastoma Multiforme Therapeutics Forecasted Market Size by Country
5.2.1 North America Glioblastoma Multiforme Therapeutics Sales in Volume by Country (2024-2029)
5.2.2 North America Glioblastoma Multiforme Therapeutics Sales in Value by Country (2024-2029)
6 Europe Glioblastoma Multiforme Therapeutics by Country
6.1 Europe Glioblastoma Multiforme Therapeutics Historic Market Size by Country
6.1.1 Europe Glioblastoma Multiforme Therapeutics Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Glioblastoma Multiforme Therapeutics Sales in Volume by Country (2018-2023)
6.1.3 Europe Glioblastoma Multiforme Therapeutics Sales in Value by Country (2018-2023)
6.2 Europe Glioblastoma Multiforme Therapeutics Forecasted Market Size by Country
6.2.1 Europe Glioblastoma Multiforme Therapeutics Sales in Volume by Country (2024-2029)
6.2.2 Europe Glioblastoma Multiforme Therapeutics Sales in Value by Country (2024-2029)
7 Asia-Pacific Glioblastoma Multiforme Therapeutics by Region
7.1 Asia-Pacific Glioblastoma Multiforme Therapeutics Historic Market Size by Region
7.1.1 Asia-Pacific Glioblastoma Multiforme Therapeutics Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Glioblastoma Multiforme Therapeutics Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Glioblastoma Multiforme Therapeutics Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Glioblastoma Multiforme Therapeutics Forecasted Market Size by Region
7.2.1 Asia-Pacific Glioblastoma Multiforme Therapeutics Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Glioblastoma Multiforme Therapeutics Sales in Value by Region (2024-2029)
8 Latin America Glioblastoma Multiforme Therapeutics by Country
8.1 Latin America Glioblastoma Multiforme Therapeutics Historic Market Size by Country
8.1.1 Latin America Glioblastoma Multiforme Therapeutics Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Glioblastoma Multiforme Therapeutics Sales in Volume by Country (2018-2023)
8.1.3 Latin America Glioblastoma Multiforme Therapeutics Sales in Value by Country (2018-2023)
8.2 Latin America Glioblastoma Multiforme Therapeutics Forecasted Market Size by Country
8.2.1 Latin America Glioblastoma Multiforme Therapeutics Sales in Volume by Country (2024-2029)
8.2.2 Latin America Glioblastoma Multiforme Therapeutics Sales in Value by Country (2024-2029)
9 Middle East and Africa Glioblastoma Multiforme Therapeutics by Country
9.1 Middle East and Africa Glioblastoma Multiforme Therapeutics Historic Market Size by Country
9.1.1 Middle East and Africa Glioblastoma Multiforme Therapeutics Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Glioblastoma Multiforme Therapeutics Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Glioblastoma Multiforme Therapeutics Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Glioblastoma Multiforme Therapeutics Forecasted Market Size by Country
9.2.1 Middle East and Africa Glioblastoma Multiforme Therapeutics Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Glioblastoma Multiforme Therapeutics Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Arbor Pharmaceuticals
10.1.1 Arbor Pharmaceuticals Company Information
10.1.2 Arbor Pharmaceuticals Introduction and Business Overview
10.1.3 Arbor Pharmaceuticals Glioblastoma Multiforme Therapeutics Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Arbor Pharmaceuticals Glioblastoma Multiforme Therapeutics Products Offered
10.1.5 Arbor Pharmaceuticals Recent Development
10.2 Bristol-Myers Squibb
10.2.1 Bristol-Myers Squibb Company Information
10.2.2 Bristol-Myers Squibb Introduction and Business Overview
10.2.3 Bristol-Myers Squibb Glioblastoma Multiforme Therapeutics Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Bristol-Myers Squibb Glioblastoma Multiforme Therapeutics Products Offered
10.2.5 Bristol-Myers Squibb Recent Development
10.3 Eisai
10.3.1 Eisai Company Information
10.3.2 Eisai Introduction and Business Overview
10.3.3 Eisai Glioblastoma Multiforme Therapeutics Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Eisai Glioblastoma Multiforme Therapeutics Products Offered
10.3.5 Eisai Recent Development
10.4 F. Hoffmann-La Roche
10.4.1 F. Hoffmann-La Roche Company Information
10.4.2 F. Hoffmann-La Roche Introduction and Business Overview
10.4.3 F. Hoffmann-La Roche Glioblastoma Multiforme Therapeutics Sales, Revenue and Gross Margin (2018-2023)
10.4.4 F. Hoffmann-La Roche Glioblastoma Multiforme Therapeutics Products Offered
10.4.5 F. Hoffmann-La Roche Recent Development
10.5 Merck
10.5.1 Merck Company Information
10.5.2 Merck Introduction and Business Overview
10.5.3 Merck Glioblastoma Multiforme Therapeutics Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Merck Glioblastoma Multiforme Therapeutics Products Offered
10.5.5 Merck Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Glioblastoma Multiforme Therapeutics Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Glioblastoma Multiforme Therapeutics Industrial Chain Analysis
11.4 Glioblastoma Multiforme Therapeutics Market Dynamics
11.4.1 Glioblastoma Multiforme Therapeutics Industry Trends
11.4.2 Glioblastoma Multiforme Therapeutics Market Drivers
11.4.3 Glioblastoma Multiforme Therapeutics Market Challenges
11.4.4 Glioblastoma Multiforme Therapeutics Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Glioblastoma Multiforme Therapeutics Distributors
12.3 Glioblastoma Multiforme Therapeutics Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
